Extended prophylaxis with aspirin does not differ significantly from rivaroxaban for venous thromboembolism prevention in patients who have undergone total hip or knee arthroplasty.
Using digital adherence devices to improve medication adherence in patients with atrial fibrillation may reduce the rate of ischemic strokes.
Anticoagulants are associated with increased risk for ischemic stroke and hemorrhage in older patients with chronic kidney disease and a new diagnosis of atrial fibrillation.
A 45-year-old man presents to the emergency department with some mental confusion and near syncope.
Treatment with direct oral anticoagulants in addition to antiplatelet therapy appears efficacious for patients with STEMI.
A 35-year-old pregnant woman presents to the emergency department with progressive dyspnea and palpitations that have worsened during the last 3 weeks.
Clinical practice guidelines for anticoagulation therapy for cardiopulmonary bypass have been developed.
Cost-effective DOACs like apixaban prevent strokes better than warfarin in patients with atrial fibrillation.
Bleeding Risk, Stroke Outcomes With Edoxaban vs Enoxaparin-Warfarin for Cardioversion of Atrial FibrillationDecember 15, 2017
In patients with atrial fibrillation at high risk for stroke, edoxaban is associated with lower rates of cardiovascular death events.
Triple therapy is associated with increased mortality risk in patients with LGIB and CAD.
Patients with atrial fibrillation who are treated with oral anticoagulants often experience renal function decline.
The chemical stability of warfarin sodium tablets is not affected by repackaging into dose administration aids.
Antithrombotic Therapy for Atrial Fibrillation and Valvular Heart Disease: New Joint Consensus StatementDecember 05, 2017
A new consensus statement provides updated guidelines for antithrombotic therapy in patients with atrial fibrillation associated with valvular heart disease.
The American College of Cardiology released an expert consensus decision pathway intended to guide clinicians in managing bleeding in patients treated with anticoagulation.
Compared with warfarin, direct oral anticoagulants lowered the risk for stroke and death risk in patients with incident atrial fibrillation.
Direct oral anticoagulant use is not associated with increased risk of major bleeding or mortality for patients with venous thromboembolism.
Genotype-guided warfarin dosing is associated with reduced risk of adverse events in hip or knee arthroplasty patients.
Venous thromboembolism events and mortality linked to genetic variant in elderly patients treated with vitamin K antagonists.
Patients with atrial fibrillation who are at a low risk for stroke do not receive a major benefit from long-term aspirin therapy.
Fewer than 45% of patients with atrial fibrillation aged 75 years or older receive anticoagulants upon hospital admission.
Novel oral anticoagulants lead to a one-fifth reduction in the risk of intraocular bleeding, compared with warfarin in patients with atrial fibrillation or venous thromboembolism.
Fondaparinux and rivaroxaban have higher efficacy of reducing venous thromboembolism after total hip or knee arthroplasty, but also an increased risk of major bleeding.
Cardiology care in patients with newly diagnosed atrial fibrillation was associated with reductions in stroke and death.
Idarucizumab can effectively reverse the anticoagulant effect of dabigatran.
Bristol-Myers Squibb is recalling one lot of Eliquis after finding that 1 of the bottles contained the wrong dosage.
A meta-analysis was conducted to examine concerns surrounding direct oral anticoagulant therapy in patients with extreme high or low body weight.
Anticoagulation treatment for patients with mechanical heart valves during pregnancy is linked to maternal and fetal risks.
A new model can help predict acute gastrointestinal bleeding, associated with increased risk of all-cause mortality.
Treating patients with at least a 17.5% predicted one-year venous thromboembolism risk may cost-effective.
Fewer adverse events were linked to electronic-health-based management of oral anticoagulation therapy.
The Cardiology Advisor Articles
- FDA Reports Combination Hypertension Treatment Discontinued
- Automated Detection of Atrial Fibrillation Through Smartwatch Technology
- Cardiovascular Outcomes of SGLT-2i vs Other Glucose-Lowering Drugs in T2D
- Outcomes With Aspirin for Primary Prevention in Heart Failure, Type 2 Diabetes
- Machine Learning Shows Potential in Diagnosing Myocardial Infarction in Patients With Chest Pain
- Digital Adherence Devices: Preventing Strokes in Afib One Reminder at a Time
- Pioglitazone Lowers Cardiovascular, Noncardiovascular Mortality in Diabetes
- Peripheral Artery Disease, DVT Risk May Increase With Varicose Veins
- Cardiorespiratory Fitness May Improve Executive Function in Mild Cognitive Impairment
- Preventing Chemotherapy-Related Cardiotoxicity in Breast Cancer
- Patent Foramen Ovale Characteristics May Predict Benefits of PFO Closure
- Low-Dose Triple Combo Therapy Effective in Hypertension
- Blood Pressure, Glucose Levels Worsened From the Great Recession
- Acute MI Hospital Mortality During Transcatheter Cardiovascular Therapeutics Meeting Dates
- A 64-Year-Old Woman With Colorectal Cancer Presents to ED With Severe Chest Pain